-transparent.png){kind=logo}
The influence of aminoglutethimide (AG) on antipyrine, theophylline, and digitoxin kinetics was examined. Antipyrine was given as a single test dose before and after 3 mo of AG treatment, whereas theophylline and digitoxin kinetics were investigated at steady state in patients receiving these drugs therapeutically before and after AG therapy. During AG treatment, mean clearance rates for antipyrine, theophylline, and digitoxin increased by 81%, 32%, and 109%. Together with earlier reports of effects of AG on warfarin and dexamethasone disposition and on its own metabolism, these findings indicate that AG is a potent inducer of drug metabolizing microsomal monooxygenases of the liver. Since many drugs known to be metabolized by this enzyme system are frequently used for concomitant conditions in patients with breast cancer, interactions with AG are to be expected.
E Lønning, and
S Kvinnsland, and
O M Bakke
March 1990,
Biopharmaceutics & drug disposition,
E Lønning, and
S Kvinnsland, and
O M Bakke
January 1986,
Cancer chemotherapy and pharmacology,
E Lønning, and
S Kvinnsland, and
O M Bakke
December 1987,
British journal of clinical pharmacology,
E Lønning, and
S Kvinnsland, and
O M Bakke
May 1976,
Clinical pharmacology and therapeutics,
E Lønning, and
S Kvinnsland, and
O M Bakke
July 1978,
The Journal of allergy and clinical immunology,
E Lønning, and
S Kvinnsland, and
O M Bakke
January 1984,
Therapeutic drug monitoring,
E Lønning, and
S Kvinnsland, and
O M Bakke
January 1994,
Drugs under experimental and clinical research,
E Lønning, and
S Kvinnsland, and
O M Bakke
April 1978,
Clinical pharmacology and therapeutics,
E Lønning, and
S Kvinnsland, and
O M Bakke
March 1995,
Clinical pharmacology and therapeutics,
E Lønning, and
S Kvinnsland, and
O M Bakke
October 1984,
British journal of clinical pharmacology,
